Warburg Research Analysts Give Fresenius SE & Co KGaA (FRE) a €80.00 Price Target

Fresenius SE & Co KGaA (FRA:FRE) has been given a €80.00 ($93.02) price objective by research analysts at Warburg Research in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. Warburg Research’s target price indicates a potential upside of 33.24% from the stock’s previous close.

Several other research analysts have also recently weighed in on the company. Independent Research set a €66.00 ($76.74) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday. Berenberg Bank set a €81.85 ($95.17) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Wednesday. Sanford C. Bernstein set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Wednesday. Commerzbank set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Wednesday. Finally, Deutsche Bank set a €85.00 ($98.84) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Friday, October 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of €77.09 ($89.64).

FRE stock opened at €60.04 ($69.81) on Wednesday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: Analyzing a company’s cash flow statement

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply